Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1962 4
1963 1
1964 4
1965 9
1966 4
1967 13
1968 2
1969 6
1970 3
1971 2
1972 5
1973 3
1974 1
1975 6
1976 2
1977 2
1978 5
1980 3
1981 1
1982 1
1983 3
1984 3
1985 6
1986 2
1987 2
1988 4
1989 9
1990 10
1991 4
1992 4
1993 6
1994 1
1995 5
1996 10
1997 4
1998 1
1999 4
2000 16
2001 10
2002 9
2003 19
2004 21
2005 19
2006 24
2007 22
2008 22
2009 24
2010 37
2011 36
2012 36
2013 22
2014 28
2015 22
2016 29
2017 30
2018 25
2019 24
2020 27
2021 27
2022 37
2023 27
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

697 results

Results by year

Filters applied: . Clear all
Page 1
Single-cell sequencing on CD8+ TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer.
Komuro H, Shinohara S, Fukushima Y, Demachi-Okamura A, Muraoka D, Masago K, Matsui T, Sugita Y, Takahashi Y, Nishida R, Takashima C, Ohki T, Shigematsu Y, Watanabe F, Adachi K, Fukuyama T, Hamana H, Kishi H, Miura D, Tanaka Y, Onoue K, Onoguchi K, Yamashita Y, Stratford R, Clancy T, Yamaguchi R, Kuroda H, Doi K, Iwata H, Matsushita H. Komuro H, et al. Among authors: fukuyama t. J Immunother Cancer. 2023 Aug;11(8):e007180. doi: 10.1136/jitc-2023-007180. J Immunother Cancer. 2023. PMID: 37544663 Free PMC article.
Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment.
Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T, Yamamoto K, Sato N, Enomoto Y, Tanaka Y, Fukuyama T, Satoh H, Kato K, Saitoh K, Ishikawa T, Soga T, Nannya Y, Fukagawa T, Nakanishi M, Kitagawa D, Kitamura T, Goyama S. Yabushita T, et al. Among authors: fukuyama t. Cell Rep. 2023 Sep 26;42(9):113098. doi: 10.1016/j.celrep.2023.113098. Epub 2023 Sep 14. Cell Rep. 2023. PMID: 37714156 Free article.
Synthesis of (-)-oxycodone.
Kimishima A, Umihara H, Mizoguchi A, Yokoshima S, Fukuyama T. Kimishima A, et al. Among authors: fukuyama t. Org Lett. 2014 Dec 5;16(23):6244-7. doi: 10.1021/ol503175n. Epub 2014 Nov 25. Org Lett. 2014. PMID: 25423610
Plasma membrane phosphatidylinositol (4,5)-bisphosphate is critical for determination of epithelial characteristics.
Kanemaru K, Shimozawa M, Kitamata M, Furuishi R, Kayano H, Sukawa Y, Chiba Y, Fukuyama T, Hasegawa J, Nakanishi H, Kishimoto T, Tsujita K, Tanaka K, Itoh T, Sasaki J, Sasaki T, Fukami K, Nakamura Y. Kanemaru K, et al. Among authors: fukuyama t. Nat Commun. 2022 May 9;13(1):2347. doi: 10.1038/s41467-022-30061-9. Nat Commun. 2022. PMID: 35534464 Free PMC article.
IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia.
Liu X, Sato N, Yabushita T, Li J, Jia Y, Tamura M, Asada S, Fujino T, Fukushima T, Yonezawa T, Tanaka Y, Fukuyama T, Tsuchiya A, Shikata S, Iwamura H, Kinouchi C, Komatsu K, Yamasaki S, Shibata T, Sasaki AT, Schibler J, Wunderlich M, O'Brien E, Mizukawa B, Mulloy JC, Sugiura Y, Takizawa H, Shibata T, Miyake K, Kitamura T, Goyama S. Liu X, et al. Among authors: fukuyama t. EMBO Mol Med. 2023 Jan 11;15(1):e15631. doi: 10.15252/emmm.202115631. Epub 2022 Dec 1. EMBO Mol Med. 2023. PMID: 36453131 Free PMC article.
Eliminating chronic myeloid leukemia stem cells by IRAK1/4 inhibitors.
Tanaka Y, Takeda R, Fukushima T, Mikami K, Tsuchiya S, Tamura M, Adachi K, Umemoto T, Asada S, Watanabe N, Morishita S, Imai M, Nagata M, Araki M, Takizawa H, Fukuyama T, Lamagna C, Masuda ES, Ito R, Goyama S, Komatsu N, Takaku T, Kitamura T. Tanaka Y, et al. Among authors: fukuyama t. Nat Commun. 2022 Jan 12;13(1):271. doi: 10.1038/s41467-021-27928-8. Nat Commun. 2022. PMID: 35022428 Free PMC article.
Total Synthesis of Tetrodotoxin.
Murakami K, Toma T, Fukuyama T, Yokoshima S. Murakami K, et al. Among authors: fukuyama t. Angew Chem Int Ed Engl. 2020 Apr 6;59(15):6253-6257. doi: 10.1002/anie.201916611. Epub 2020 Feb 19. Angew Chem Int Ed Engl. 2020. PMID: 31985136
Total Synthesis of Haliclonin A.
Jin Y, Orihara K, Kawagishi F, Toma T, Fukuyama T, Yokoshima S. Jin Y, et al. Among authors: fukuyama t. Angew Chem Int Ed Engl. 2021 Apr 19;60(17):9666-9671. doi: 10.1002/anie.202016343. Epub 2021 Mar 11. Angew Chem Int Ed Engl. 2021. PMID: 33559237
MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis.
Hayashi Y, Kawabata KC, Tanaka Y, Uehara Y, Mabuchi Y, Murakami K, Nishiyama A, Kiryu S, Yoshioka Y, Ota Y, Sugiyama T, Mikami K, Tamura M, Fukushima T, Asada S, Takeda R, Kunisaki Y, Fukuyama T, Yokoyama K, Uchida T, Hagihara M, Ohno N, Usuki K, Tojo A, Katayama Y, Goyama S, Arai F, Tamura T, Nagasawa T, Ochiya T, Inoue D, Kitamura T. Hayashi Y, et al. Among authors: fukuyama t. Cell Rep. 2022 May 10;39(6):110805. doi: 10.1016/j.celrep.2022.110805. Cell Rep. 2022. PMID: 35545056 Free article.
The molecular basis of myeloid malignancies.
Kitamura T, Inoue D, Okochi-Watanabe N, Kato N, Komeno Y, Lu Y, Enomoto Y, Doki N, Uchida T, Kagiyama Y, Togami K, Kawabata KC, Nagase R, Horikawa S, Hayashi Y, Saika M, Fukuyama T, Izawa K, Oki T, Nakahara F, Kitaura J. Kitamura T, et al. Among authors: fukuyama t. Proc Jpn Acad Ser B Phys Biol Sci. 2014;90(10):389-404. doi: 10.2183/pjab.90.389. Proc Jpn Acad Ser B Phys Biol Sci. 2014. PMID: 25504228 Free PMC article. Review.
697 results